» Articles » PMID: 10720935

Defects in Processing and Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2000 Mar 18
PMID 10720935
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is caused by inherited mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel expressed in epithelial tissues. Most mutations in CF patients result in rapid intracellular degradation of the CFTR protein. While this defect is thought to result from abnormal protein folding, it is unclear how mutant and wild-type (WT) proteins differ in structure, how the cell is able to distinguish these differences, and how the fate of the mutant protein is determined. By examining the initial steps of CFTR assembly into the endoplasmic reticulum (ER) membrane, it has recently been shown that CFTR utilizes two redundant translocation pathways to direct N-terminus folding events. Mutations that block one pathway therefore do not alter transmembrane topology, but rather appear to disrupt intracellular trafficking through perturbations in higher order tertiary structure. These studies suggest that cellular quality control machinery acts at least in part, by monitoring proper interactions between CFTR subdomains. The end result of this process is the conversion of misfolded CFTR into a membrane-bound, polyubiquitinated complex. This complex recruits cytosolic degradation machinery to the endoplasmic reticulum membrane where CFTR is degraded as it is extracted from the lipid bilayer. Understanding how cellular machinery mediates this process will be an important step in designing strategies to modify protein folding and degradation in CF and related ion channelopathies.

Citing Articles

Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.

Bongiorno R, Ludovico A, Moran O, Baroni D Int J Mol Sci. 2023; 24(16).

PMID: 37629017 PMC: 10454486. DOI: 10.3390/ijms241612838.


More Than Just Simple Interaction between STIM and Orai Proteins: CRAC Channel Function Enabled by a Network of Interactions with Regulatory Proteins.

Berlansky S, Humer C, Sallinger M, Frischauf I Int J Mol Sci. 2021; 22(1).

PMID: 33466526 PMC: 7796502. DOI: 10.3390/ijms22010471.


Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies.

Almughem F, Aldossary A, Tawfik E, Alomary M, Alharbi W, Alshahrani M Pharmaceutics. 2020; 12(7).

PMID: 32630625 PMC: 7407299. DOI: 10.3390/pharmaceutics12070616.


Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.

Amico G, Brandas C, Moran O, Baroni D Int J Mol Sci. 2019; 20(21).

PMID: 31683989 PMC: 6862496. DOI: 10.3390/ijms20215463.


Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits.

Enogieru O, Ung P, Yee S, Schlessinger A, Giacomini K Hum Mutat. 2019; 40(7):983-995.

PMID: 30950137 PMC: 7137536. DOI: 10.1002/humu.23758.